LIB Therapeutics and Sun Pharma announce manufacturing agreement for Lerodalcibep, a PCSK9 Inhibitor EP News Bureau Sep 28, 2026 Lerodalcibep is approved in the EU under the brand name Lyrokaul for the treatment of adult patients with hypercholesterolaemia…
Lerodalcibep can be a treatment option for patients requiring additional LDL-C reduction: GlobalData GlobalData Mar 4, 2025 Lerodalcibep is a novel therapy designed to lower low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic…
